Michelle Mahler

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan et al. · The Lancet Oncology · 2015 · 410 citations

Medicine, Immunology, Pharmacotherapy +12

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Jennifer R. Brown, Javid J. Moslehi, Susan O’Brien et al. · Haematologica · 2017 · 258 citations · Full text

Medicine, Oncology, Pharmacology +15

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

Graeme Fraser, Paula Cramer, Rodrigo Santucci Alves da Silva et al. · Leukemia · 2018 · 117 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis

Jennifer R. Brown, Javid J. Moslehi, Michael S. Ewer et al. · British Journal of Haematology · 2018 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Safety and Immunogenicity of the Tetravalent Protein-Conjugated Meningococcal Vaccine (MCV4) in Recipients of Related and Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Michelle Mahler, Ying Taur, R Jean et al. · Biology of Blood and Marrow Transplantation · 2011 · 46 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +11